

Supplementary Online Content

Andersson NW, Thomsen SF, Andersen JT. Evaluation of association between oral and topical terbinafine use in pregnancy and risk of major malformations and spontaneous abortion. *JAMA Dermatol*. Published online March 4, 2020.
doi:10.1001/jamadermatol.2020.0142

eMethods. Definition of the Major Malformations

eTable 1. Definition of Covariates Included in Propensity Score With Definitions and Data Sources

eTable 2. Number of Missing Values (Percentages) for the Unmatched Study Cohorts

eTable 3. Baseline Characteristics of Unmatched Cohorts of Oral and Topical Terbinafine Exposed and Unexposed Pregnancies for Analyses of the Primary Outcome

eTable 4. Baseline Characteristics of Unmatched Cohorts of Oral and Topical Terbinafine Exposed and Unexposed Pregnancies for Analyses of the Secondary Outcome

eTable 5. Baseline Characteristics of Matched Cohorts of Oral and Topical Terbinafine Exposed and Unexposed Pregnancies on Propensity Scores for Analyses of the Secondary Outcome

eTable 6. Standardized Differences Comparison of Oral and Topical Terbinafine-Exposed and Unexposed Pregnancies Before Propensity Score Matching

eTable 7. Standardized Differences for Comparison of Oral and Topical Terbinafine-Exposed and Unexposed Pregnancies After Propensity Score Matching

eTable 8. Sensitivity Analyses for the Association Between Oral Terbinafine Use and Spontaneous Abortion as Compared With Unexposed Pregnancies Where Restricting According to Different Exposure Time Window Definitions

eReferences

This supplementary material has been provided by the authors to give readers additional information about their work.

eMethods.

Definition of the major malformations.

Outcome cases of major malformations diagnosed within the first year of life were identified through the National Patient Registry.¹ Major malformations were defined according to the European Surveillance of Congenital Anomalies (EUROCAT) classification system of subgroups of major congenital anomalies, while excluding minor malformations according to EUROCAT exclusion list.² Major congenital malformations of known causes were excluded, including: genetic syndromes (ICD-10: Q447B, Q619A, Q751, Q754, Q771, Q772, Q780, Q796, Q85, Q87), malformation syndromes with known causes (ICD-10: Q86), and malformations due to chromosomal aberrations (ICD-10: Q90-99).

eTable 1. Definition of covariates included in propensity score with definitions and data sources.

Variable	Categories	Data source
Age at pregnancy onset	≤19, 20-24, 25-29, 30-34, ≥35	Central Person Registry
Married or living with partner	yes/no	Central Person Registry
Place of birth	Denmark, Europe, Outside Europe	Central Person Registry
Region of residence	The Capital Region of Denmark, Region Zealand, The Region of Southern Denmark, Central Denmark Region, The North Denmark Region	Central Person Registry
Gross household income	Quartiles	Statistic Denmark
Education level, years	≤11, 12-13, 14-15, ≥16	Statistic Denmark
Year of pregnancy onset	1997-2000, 2001-2004, 2005-2008, 2009-2012, 2013-2016	Medical Birth Registry
Parity ^a	0, 1,2, ≥3	Medical Birth Registry
Multiple birth pregnancy ^a	yes/no	Medical Birth Registry
Smoking during pregnancy ^a	yes/no	Medical Birth Registry
Previous pregnancy with major malformation or spontaneous abortion ^b	yes/no	National Patient Registry
Antidiabetic drug use in past year	A10A, A10B	Registry of Medicinal Product Statistics
Drugs used for IVF in past 3 months	G03G, G03DA04, H01CC, L02AE01	Registry of Medicinal Product Statistics
No. of drugs used in past year	0, 1-2, 3-4, ≥5	Registry of Medicinal Product Statistics
No. of days of hospitalization in past year	0, 1-2, ≥3	National Patient Registry
No. of outpatient contacts in past year	0, 1-2, ≥3	National Patient Registry

ICD-10: international classification of disease, version 10; ATC: anatomic therapeutic chemical; IVF: in vitro fertilization. ^aCovariate was available for analyses on live births only. ^bPrevious pregnancy with major malformations and spontaneous abortions variables were included in the analyses of major malformations and spontaneous abortion, respectively.

eTable 2. Number of missing values (percentages) for the unmatched study cohorts.

Variable	For analysis of major malformations (n=1,030,873)	For analysis of spontaneous abortion (n=1,419,951)
Age at pregnancy onset	0	0
Married or living with partner	13763 (1.3)	20618 (1.5)
Place of birth	315 (0.0)	464 (0.0)
Region of residence	0	50 (0.0)
Gross household income	676 (0.1)	1124 (0.1)
Education level, years	42486 (4.1)	57966 (4.1)
Year of pregnancy onset	0	0
Parity	5640 (0.5)	NA
Multiple birth pregnancy	0	NA
Smoking during pregnancy	23991 (2.3)	NA
Previous pregnancy with the same adverse fetal outcome	0	0
Antidiabetic drug use in past year	0	0
Drugs used for IVF in past 3 months	0	0
No. of drugs used in past year	0	0
Hospital care utilization in past year	0	0

NA: not available.

eTable 3. Baseline characteristics of unmatched cohorts of oral and topical terbinafine exposed and unexposed pregnancies for analyses of the primary outcome. Values are numbers (percentages) unless otherwise stated.

Characteristics	Unmatched cohort of oral and topical terbinafine exposed and unexposed pregnancies for analysis of major malformations		
	Oral terbinafine (n=522)	Topical terbinafine exposed (n=1476)	Unexposed (n=1,028,875)
Age at pregnancy onset			
≤19	7 (1.3)	23 (1.6)	14626 (1.4)
20-24	50 (9.6)	215 (14.6)	114989 (11.2)
25-29	162 (31.0)	506 (34.3)	338300 (32.9)
30-34	201 (38.5)	503 (34.1)	367092 (35.7)
≥35	102 (19.5)	229 (15.5)	193868 (18.8)
Married or living with partner	445 (85.3)	1283 (86.9)	902624 (87.7)
Place of birth			
Denmark	423 (81.0)	1256 (85.1)	868274 (84.4)
Europe	32 (6.1)	76 (5.2)	57870 (5.6)
Outside of Europe	67 (12.8)	144 (9.8)	102731 (10.0)
Region of residence			
The Capital Region of Denmark	149 (28.5)	432 (29.3)	334580 (32.5)
Region Zealand	58 (11.1)	205 (13.9)	140563 (13.7)
The Region of Southern Denmark	109 (20.9)	293 (19.9)	188987 (18.4)
Central Denmark Region	149 (28.5)	387 (26.2)	260286 (25.3)
The North Denmark Region	57 (10.9)	159 (10.8)	104459 (10.2)
Gross household income, quartile			
1	129 (24.7)	405 (27.4)	257729 (25.1)
2	124 (23.8)	448 (30.4)	257057 (25.0)
3	134 (25.7)	376 (25.5)	257045 (25.0)
4	135 (25.9)	247 (16.7)	257044 (25.0)
Education level, years			
≤11	124 (23.8)	383 (26.0)	226313 (22.0)
12-13	93 (17.8)	232 (15.7)	151944 (14.8)
14-15	132 (25.3)	402 (27.2)	262793 (25.5)
≥16	173 (33.1)	459 (31.1)	387825 (37.7)
Year of pregnancy onset			
1997-2000	69 (13.2)	523 (35.4)	221624 (21.5)
2001-2004	104 (19.9)	352 (23.9)	220780 (21.5)
2005-2008	134 (25.7)	268 (18.2)	220728 (21.5)
2009-2012	122 (23.4)	194 (13.1)	202882 (19.7)
2013-2016	93 (17.8)	139 (9.4)	162861 (15.8)
Parity			
1	228 (43.7)	699 (47.4)	466403 (45.3)
2	177 (33.9)	529 (35.8)	374786 (36.4)
≥3	117 (22.4)	248 (16.8)	187686 (18.2)
Multiple birth pregnancy	11 (2.1)	33 (2.2)	42914 (4.2)
Smoking during pregnancy	82 (15.7)	272 (18.4)	161613 (15.7)
Previous pregnancy with major malformations outcome	13 (2.5)	16 (1.1)	18043 (1.8)
Antidiabetic drug use in past year	5 (1.0)	21 (1.4)	12484 (1.2)
Drugs used for IVF in past 3	16 (3.1)	87 (5.9)	63237 (6.2)

months			
No. of drugs used in past year			
1-2	170 (32.6)	487 (33.0)	432845 (42.1)
3-4	133 (25.5)	400 (27.1)	210313 (20.4)
≥5	173 (33.1)	381 (25.8)	138522 (13.5)
No. of hospitalization in past year			
1	74 (14.2)	226 (15.3)	127810 (12.4)
2	9 (1.7)	27 (1.8)	22795 (2.2)
≥3	5 (1.0)	15 (1.0)	7220 (0.7)
No. of outpatient contacts in past year			
1	82 (15.7)	207 (14.0)	141349 (13.7)
2	27 (5.2)	84 (5.7)	51211 (5.0)
≥3	11 (2.1)	36 (2.4)	23885 (2.3)

IQR: Interquartile range. IVF: in vitro fertilization.

eTable 4. Baseline characteristics of unmatched cohorts of oral and topical terbinafine exposed and unexposed pregnancies for analyses of the secondary outcome. Values are numbers (percentages) unless otherwise stated.

Characteristics	Unmatched cohort of oral and topical terbinafine exposed and unexposed pregnancies for analysis of spontaneous abortion		
	Oral terbinafine (n=891)	Topical terbinafine exposed (n=3194)	Unexposed (n=1,415,866)
GA at first filled prescription for terbinafine, median (IQR)	11 (-2-28)	66.5 (31-112)	
Age at pregnancy onset			
≤19	39 (4.4)	91 (2.9)	55139 (3.9)
20-24	110 (12.4)	481 (15.1)	186237 (13.2)
25-29	240 (26.9)	1064 (33.3)	424531 (30.0)
30-34	282 (31.7)	997 (31.2)	457704 (32.3)
≥35	220 (24.7)	561 (17.6)	292255 (20.6)
Married or living with partner	696 (78.1)	2687 (84.1)	1154141 (81.5)
Place of birth			
Denmark	734 (82.4)	2736 (85.7)	1190579 (84.1)
Europe	50 (5.6)	167 (5.2)	78791 (5.6)
Outside of Europe	107 (12.0)	291 (9.1)	146496 (10.4)
Region of residence			
The Capital Region of Denmark	488 (54.8)	1234 (38.6)	724948 (51.2)
Region Zealand	64 (7.2)	376 (11.8)	140141 (9.9)
The Region of Southern Denmark	113 (12.7)	506 (15.8)	187992 (13.3)
Central Denmark Region	166 (18.6)	769 (24.1)	258906 (18.3)
The North Denmark Region	60 (6.7)	309 (9.7)	103879 (7.3)
Gross household income, quartile			
1	222 (24.9)	733 (23.0)	354811 (25.1)
2	214 (24.0)	953 (29.8)	353694 (25.0)
3	207 (23.2)	872 (27.3)	253702 (25.0)
4	248 (27.8)	636 (19.9)	353659 (25.0)
Education level, years			
≤11	266 (30.0)	899 (28.2)	384341 (27.2)
12-13	143 (16.1)	504 (15.8)	211347 (14.9)
14-15	204 (22.9)	845 (26.5)	340875 (24.1)
≥16	278 (31.2)	946 (29.6)	479303 (33.9)
Year of pregnancy onset			
1997-2000	134 (15.0)	1096 (34.3)	308006 (21.8)
2001-2004	165 (18.5)	766 (24.0)	306139 (21.6)
2005-2008	214 (24.0)	605 (18.9)	303808 (21.5)
2009-2012	213 (23.9)	408 (12.8)	276027 (19.5)
2013-2016	165 (18.5)	319 (10.0)	221886 (15.7)
Previous pregnancy with spontaneous abortion	150 (16.8)	489 (15.3)	216362 (15.3)
Previous pregnancy with induced abortion	153 (17.2)	317 (9.9)	191454 (13.5)
Antidiabetic drug use in past year	10 (1.1)	57 (1.8)	15620 (1.1)
Drugs used for IVF in past 3 months	25 (2.8)	169 (5.3)	72965 (5.2)
No. of drugs used in past year			

1-2	283 (31.8)	1088 (34.1)	591596 (41.8)
3-4	230 (25.8)	806 (25.2)	273830 (19.3)
≥5	300 (33.7)	824 (25.8)	173424 (12.3)
No. of hospitalization in past year			
1	130 (14.6)	465 (14.6)	180986 (12.8)
2	22 (2.5)	72 (2.3)	33186 (2.3)
≥3	10 (1.1)	36 (1.1)	11274 (0.8)
No. of outpatient contacts in past year			
1	146 (16.4)	444 (13.9)	196011 (13.8)
2	51 (5.7)	188 (5.9)	72098 (5.1)
≥3	23 (2.6)	77 (2.4)	33964 (2.4)

IQR: Interquartile range. IVF: in vitro fertilization.

Table 5. Baseline characteristics of matched cohorts of oral and topical terbinafine exposed and unexposed pregnancies on propensity scores for analyses of the secondary outcome. Values are numbers (percentages) unless otherwise stated.

Characteristics	Matched cohort of oral terbinafine exposed and unexposed pregnancies for analysis of spontaneous abortion		Matched cohort of topical terbinafine exposed and unexposed pregnancies for analysis of spontaneous abortion		Matched cohort of oral and topical terbinafine exposed pregnancies for analysis of spontaneous abortion	
	Oral terbinafine (n=891)	Unexposed (n=8910)	Topical terbinafine exposed (n=3174)	Unexposed (n=31740)	Oral terbinafine (n=617)	Topical terbinafine exposed (n=617)
GA at first filled prescription for terbinafine, median (IQR)	11 (-2-28)		66 (31-111)		20 (8-36)	20 (7-37)
Age at pregnancy onset						
≤19	39 (4.4)	464 (5.2)	91 (2.9)	858 (2.7)	28 (4.5)	26 (4.2)
20-24	110 (12.4)	1113 (12.5)	479 (15.1)	4764 (15.0)	92 (14.9)	92 (14.9)
25-29	240 (26.9)	2217 (24.9)	1058 (33.3)	10826 (34.1)	159 (25.8)	160 (25.9)
30-34	282 (31.7)	2914 (32.7)	986 (31.1)	9999 (31.5)	200 (32.4)	182 (29.5)
≥35	220 (24.7)	2202 (24.7)	560 (17.6)	5293 (16.7)	138 (22.4)	157 (25.5)
Married or living with partner	696 (78.1)	6943 (77.9)	2670 (84.1)	26900 (84.8)	480 (77.8)	471 (76.3)
Place of birth						
Denmark	734 (82.4)	7367 (82.7)	2719 (85.7)	27441 (86.5)	511 (82.8)	510 (82.7)
Europe	50 (5.6)	484 (5.4)	167 (5.3)	1622 (5.1)	40 (6.5)	39 (6.3)
Outside of Europe	107 (12.0)	1059 (11.9)	288 (9.1)	2677 (8.4)	66 (10.7)	68 (11.0)
Region of residence						
The Capital Region of Denmark	488 (54.8)	4950 (55.6)	1224 (38.6)	11685 (36.8)	320 (51.9)	329 (53.3)
Region Zealand	64 (7.2)	603 (6.8)	372 (11.7)	3915 (12.3)	52 (8.4)	50 (8.1)
The Region of Southern Denmark	113 (12.7)	1152 (12.9)	505 (15.9)	5110 (16.1)	77 (12.5)	69 (11.2)
Central Denmark Region	166 (18.6)	1621 (18.2)	766 (24.1)	7858 (24.8)	118 (19.1)	119 (19.3)
The North Denmark Region	60 (6.7)	584 (6.6)	307 (9.7)	3172 (10.0)	50 (8.1)	50 (8.1)
Gross household income, quartile						
1	222 (24.9)	2158 (24.2)	730 (23.0)	7050 (22.2)	171 (27.7)	183 (29.7)
2	214 (24.0)	2093 (23.5)	945 (29.8)	9382 (29.6)	143 (23.2)	144 (23.3)
3	207 (23.2)	2088 (23.4)	865 (27.3)	8828 (27.8)	131 (21.2)	119 (19.3)
4	248 (27.8)	2571 (28.9)	634 (20.0)	6480 (20.4)	172 (27.9)	171 (27.7)
Education level,						

years						
≤11	266 (30.0)	2710 (30.4)	890 (28.0)	8822 (27.8)	194 (31.4)	185 (30.0)
12-13	143 (16.1)	1364 (15.3)	501 (15.8)	4933 (15.5)	93 (15.1)	98 (15.9)
14-15	204 (22.9)	2016 (22.6)	842 (26.5)	8511 (26.8)	153 (24.8)	145 (23.5)
≥16	278 (31.2)	2820 (31.7)	941 (29.7)	9474 (29.9)	177 (28.7)	189 (30.6)
Year of pregnancy onset						
1997-2000	134 (15.0)	1429 (16.0)	1093 (34.4)	11072 (34.9)	122 (19.8)	128 (20.8)
2001-2004	165 (18.5)	1605 (18.0)	757 (23.9)	7530 (23.7)	126 (20.4)	132 (21.4)
2005-2008	214 (24.0)	2180 (24.5)	602 (19.0)	5952 (18.8)	142 (23.0)	143 (23.2)
2009-2012	213 (23.9)	2121 (23.8)	406 (12.8)	4067 (12.8)	125 (20.3)	118 (19.1)
2013-2016	165 (18.5)	1575 (17.7)	316 (10.0)	3119 (9.8)	102 (16.5)	96 (15.6)
Previous pregnancy with spontaneous abortion	150 (16.8)	1252 (14.1)	486 (15.3)	4383 (13.8)	83 (13.5)	82 (13.3)
Previous pregnancy with induced abortion	153 (17.2)	1474 (16.5)	316 (10.0)	2756 (8.7)	103 (16.7)	98 (15.9)
Antidiabetic drug use in past year	10 (1.1)	108 (1.2)	55 (1.7)	454 (1.4)	7 (1.1)	5 (0.8)
Drugs used for IVF in past 3 months	25 (2.8)	293 (3.3)	168 (5.3)	1576 (5.0)	19 (3.1)	21 (3.4)
No. of drugs used in past year						
1-2	283 (31.8)	2781 (31.2)	1079 (34.0)	10854 (34.2)	188 (30.5)	181 (29.3)
3-4	230 (25.8)	2307 (25.9)	801 (25.2)	8385 (26.4)	153 (24.8)	159 (25.8)
≥5	300 (33.7)	3027 (34.0)	819 (25.8)	7733 (24.4)	216 (35.0)	216 (35.0)
No. of hospitalization in past year						
1	130 (14.6)	1272 (14.3)	461 (14.5)	4259 (13.4)	95 (15.4)	92 (14.9)
2	22 (2.5)	171 (1.9)	71 (2.2)	541 (1.7)	13 (2.1)	8 (1.3)
≥3	10 (1.1)	87 (1.0)	36 (1.1)	212 (0.7)	8 (1.3)	12 (1.9)
No. of outpatient contacts in past year						
1	146 (16.4)	1475 (16.6)	441 (13.9)	4213 (13.3)	92 (14.9)	92 (14.9)
2	51 (5.7)	468 (5.3)	187 (5.9)	1460 (4.6)	30 (4.9)	32 (5.2)
≥3	23 (2.6)	167 (1.9)	77 (2.4)	567 (1.8)	17 (2.8)	16 (2.6)

IQR: Interquartile range. IVF: in vitro fertilization.

eTable 6. Standardized differences comparison of oral and topical terbinafine exposed and unexposed pregnancies before propensity score matching. Values are percentages (%).

Characteristics	Unmatched cohorts for analyses of major malformations			Unmatched cohorts for analyses of spontaneous abortion		
	Oral terbinafine vs. unexposed	Topical terbinafine vs. unexposed	Oral vs. topical terbinafine	Oral terbinafine vs. unexposed	Topical terbinafine vs. unexposed	Oral vs. topical terbinafine
Age at pregnancy onset						
≤19	0.7	1.1	1.7	2.4	5.8	8.2
20-24	5.2	10.1	15.0	2.4	5.5	8.0
25-29	4.0	3.0	6.8	6.8	7.2	13.9
30-34	5.9	3.4	8.8	1.5	2.4	1.0
≥35	1.8	8.8	10.6	9.7	7.8	17.6
Married or living with partner	7.3	2.4	4.8	8.5	6.9	15.4
Place of birth						
Denmark	8.9	2.0	10.7	5.6	4.4	8.9
Europe	2.2	2.1	4.5	0.2	1.5	1.7
Outside of Europe	9.0	0.8	9.4	5.3	4.2	9.4
Region of residence						
The Capital Region of Denmark	8.6	7.0	1.9	7.2	25.5	32.7
Region Zealand	7.8	0.7	8.2	9.7	6.0	15.7
The Region of Southern Denmark	6.3	3.8	3.0	1.8	7.3	9.0
Central Denmark Region	7.3	2.1	5.3	0.9	14.2	13.3
The North Denmark Region	2.5	2.0	0.1	2.4	8.4	10.7
Gross household income, quartile						
1	0.8	5.4	5.1	0.3	5.0	4.9
2	2.9	12.0	10.6	2.2	10.9	11.4
3	1.6	1.1	8.8	4.1	5.3	14.6
4	2.0	20.4	23.6	6.5	12.2	19.9
Education level, years						
≤11	4.2	9.3	5.1	6.0	2.2	3.6
12-13	8.3	2.6	5.7	3.1	2.4	0.8
14-15	0.6	3.8	4.0	2.8	5.5	8.2
≥16	9.5	13.9	4.0	5.7	9.1	3.5
Year of pregnancy onset						
1997-2000	22.1	31.2	53.3	17.4	28.2	45.9
2001-2004	3.8	5.7	10.1	7.8	5.6	13.3
2005-2008	10.0	8.3	18.5	6.1	6.3	12.4

2009-2012	8.9	17.8	26.7	10.7	18.4	29.0
2013-2016	5.3	19.4	24.8	7.6	17.1	24.6
Parity						
1	3.3	4.1	7.3	NA	NA	NA
2	5.3	1.2	4.2	NA	NA	NA
≥3	10.4	3.8	14.2	NA	NA	NA
Multiple birth pregnancy	11.9	11.0	2.5	NA	NA	NA
Smoking during pregnancy	0.0	7.2	7.0	NA	NA	NA
Previous pregnancy with the same outcome	5.1	5.7	10.7	1.9	0.1	2.1
Previous pregnancy with induced abortion	NE	NE	NE	10.1	11.2	21.2
Antidiabetic drug use in past year	2.5	1.8	4.2	0.2	5.7	5.5
Drugs used for IVF in past 3 months	14.7	1.1	13.5	12.0	0.6	12.6
No. of drugs used in past year						
1-2	19.7	18.8	0.7	20.9	16.0	6.5
3-4	12.0	15.7	0.8	15.5	14.2	0.2
≥5	47.9	31.5	11.3	52.7	35.1	15.6
No. of hospitalization in past year						
1	5.2	8.4	3.0	5.3	5.2	0.1
2	3.5	2.7	1.7	0.8	0.6	1.4
≥3	2.8	3.4	0.5	3.4	3.4	0.0
No. of outpatient contacts in past year						
1	5.6	0.8	5.1	7.1	0.2	6.8
2	0.9	3.2	2.6	2.8	3.5	0.7
≥3	1.5	0.8	2.1	1.2	0.1	1.1

IQR: Interquartile range. IVF: in vitro fertilization. NA: not available. NE: not estimated.

eTable 7. Standardized differences for comparison of oral and topical terbinafine exposed and unexposed pregnancies after propensity score matching. Values are percentages (%).

Characteristics	Matched cohorts for analyses of major malformations			Matched cohorts for analyses of spontaneous abortion		
	Oral terbinafine vs. unexposed	Topical terbinafine vs. unexposed	Oral vs. topical terbinafine	Oral terbinafine vs. unexposed	Topical terbinafine vs. unexposed	Oral vs. topical terbinafine
Age at pregnancy onset						
≤19	5.1	2.3	3.6	3.9	1.0	1.6
20-24	0.2	0.7	2.6	0.4	0.2	0.0
25-29	1.2	1.2	1.3	4.7	1.6	0.4
30-34	3.3	1.1	0.4	2.3	0.9	6.3
≥35	4.2	4.6	3.0	0.1	2.6	7.2
Married or living with partner	1.7	1.8	2.8	0.5	1.7	3.5
Place of birth						
Denmark	2.7	4.0	3.6	0.8	2.3	0.4
Europe	6.3	1.8	1.7	0.8	0.7	0.7
Outside of Europe	1.1	3.5	3.1	0.4	2.3	1.0
Region of residence						
The Capital Region of Denmark	2.3	0.3	2.6	1.6	3.6	2.9
Region Zealand	1.0	0.8	2.5	1.6	1.9	1.2
The Region of Southern Denmark	0.6	0.5	1.9	0.7	0.5	4.0
Central Denmark Region	0.1	0.3	0.4	1.1	1.5	0.4
The North Denmark Region	3.0	0.2	0.6	0.7	1.1	0.0
Gross household income, quartile						
1	2.4	0.5	6.8	1.6	1.9	4.3
2	2.9	1.9	2.9	1.2	0.5	0.4
3	2.7	1.2	3.8	0.5	1.3	4.8
4	2.5	0.4	0.4	2.3	1.1	0.4
Education level, years						
≤11	1.2	1.7	3.2	1.2	0.6	3.2
12-13	1.3	1.3	1.0	2.0	0.7	2.2
14-15	1.3	0.2	0.0	0.6	0.7	3.0
≥16	0.9	0.4	2.1	1.0	0.4	4.3
Year of pregnancy onset						
1997-2000	1.9	1.3	1.7	2.8	0.9	2.4
2001-2004	0.5	0.3	2.5	1.3	0.3	2.4
2005-2008	3.7	1.1	3.6	1.1	0.6	0.4
2009-2012	0.3	0.7	2.8	0.2	0.1	2.9
2013-2016	7.1	1.1	0.0	2.2	0.4	2.7

Parity						
1	2.4	2.1	0.0	NA	NA	NA
2	4.0	0.0	2.9	NA	NA	NA
≥3	1.7	2.8	3.4	NA	NA	NA
Multiple birth pregnancy	1.7	1.2	1.3	NA	NA	NA
Smoking during pregnancy	0.4	1.9	1.6	NA	NA	NA
Previous pregnancy with the same outcome	1.1	1.1	0.0	1.5	4.3	0.5
Previous pregnancy with induced abortion	NE	NE	NE	1.7	4.4	2.2
Antidiabetic drug use in past year	4.6	3.0	1.9	0.8	2.4	3.3
Drugs used for IVF in past 3 months	1.7	2.6	1.1	2.8	1.5	1.8
No. of drugs used in past year						
1-2	1.4	0.1	4.6	1.2	0.4	2.5
3-4	3.6	2.5	0.4	0.2	2.7	2.2
≥5	2.0	2.5	0.8	0.6	3.3	0.0
No. of hospitalization in past year						
1	6.0	4.1	5.2	0.9	3.2	1.4
2	0.7	3.9	2.8	3.8	3.8	6.3
≥3	3.2	1.5	0.0	1.4	4.9	5.1
No. of outpatient contacts in past year						
1	6.3	0.6	3.3	0.5	1.8	0.0
2	1.1	4.9	5.6	2.1	5.8	1.5
≥3	1.9	3.5	1.3	4.8	4.5	1.0

IQR: Interquartile range. IVF: in vitro fertilization. NA: not available. NE: not estimated.

eTable 8. Sensitivity analyses for the association between oral terbinafine use and spontaneous abortion as compared with unexposed pregnancies where restricting according to different exposure time window definitions.

Oral terbinafine exposed vs. unexposed for analysis of spontaneous abortion	No. with spontaneous abortion/total no. (%)	Hazard Ratio (95% CI)
Oral terbinafine prescription filled later than gestational week 5		
Oral terbinafine	14/165 (8.5%)	1.13 (0.65-1.95)
Unexposed	140/1650 (8.5%)	1.00 (reference)
Oral terbinafine exposure interval restricted to day 0-154		
Oral terbinafine	64/637 (10.1%)	1.05 (0.81-1.36)
Unexposed	643/6370 (10.1%)	1.00 (reference)

CI: Confidence interval

eReferences

1. Lyng E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public Health*. 2011;39(7_suppl):30-33. doi:10.1177/1403494811401482
2. EUROCAT Guide 1.4. Instructions for the registration and surveillance of congenital anomalies. Available at: https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/Full_Guide_1_4_version_28_DEC2018.pdf. Retrieved May 16, 2019.